MDWD
Q3 2026 EPS Estimate
$-0.76
Aug 13, 2026 · Reports before open
Revenue Estimate
$3M
FY2029E EPS$0.62
FY2030E EPS$2.39

Analyst Sentiment

Wall St. Consensus
Buy
13 analysts·Moderate coverage
75
Score
13 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
13100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$22.00
+48.6%
Consensus
$27.00
+82.4%
Bull
$32.00
+116.2%
12-Month Target Range13 analysts
$22.00$27.00$32.00
Current $14.80Consensus
Current Price
$14.80
Upside to Consensus
$12.20

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+36.26%
EPS
FY2028
Rev+52.49%
EPS
FY2029
Rev+116.83%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$24M$33M$50M$109M$168M
Low$23M$32M$50M$104M$160M
High$25M$34M$50M$113M$176M
EBITDA Avg$-17M$-23M$-34M$-74M$-115M
Low$-17M$-23M$-34M$-78M$-120M
High$-15M$-22M$-34M$-71M$-110M
EBIT Avg$-17M$-24M$-36M$-78M$-121M
Low$-18M$-25M$-36M$-81M$-126M
High$-16M$-23M$-36M$-74M$-115M
Net Income Avg$-30M$-24M$-14M$7M$27M
Low$-32M$-30M$-17M$7M$26M
High$-23M$-19M$-11M$7M$29M
EPS Avg$-2.31$-2.13$-1.14$0.62$2.39
Low$-2.78$-2.61$-1.50$0.58$2.24
High$-2.01$-1.68$-0.93$0.65$2.52
Analysts (Rev / EPS)6 / 56 / 53 / 32 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$9M$11M$7M$8M$8M$9M$8M$9M
Low$7M$9M$6M$6M$7M$7M$6M$7M
High$10M$13M$9M$9M$10M$11M$10M$10M
EBITDA Avg$-6M$-8M$-5M$-5M$-6M$-6M$-6M$-6M
Low$-7M$-9M$-6M$-6M$-7M$-8M$-7M$-7M
High$-5M$-6M$-4M$-4M$-4M$-5M$-4M$-5M
EBIT Avg$-6M$-8M$-5M$-6M$-6M$-7M$-6M$-6M
Low$-7M$-9M$-6M$-6M$-7M$-8M$-7M$-7M
High$-5M$-6M$-4M$-4M$-5M$-5M$-5M$-5M
Net Income Avg$-9M$-8M$-8M$-8M$-7M$-6M
Low$-11M$-10M$-10M$-9M$-8M$-8M
High$-6M$-6M$-6M$-5M$-5M$-4M
EPS Avg$-0.69$-0.64$-0.62$-0.60$-0.53$-0.48
Low$-0.87$-0.78$-0.75$-0.72$-0.64$-0.58
High$-0.49$-0.45$-0.44$-0.42$-0.37$-0.34
Analysts (Rev / EPS)6 / 55 / 13 / 13 / 13 / 13 / 12 / 22 / 2

Earnings Surprises

Recent Analyst Actions

May 28, 2026Industrial Alliance Securities
MediWound price target lowered to $22 from $25 at Alliance Global
Target:$22.00
+51.1%from $14.56
May 27, 2026Oppenheimer
MediWound Ltd (MDWD) PT Lowered to $32 at Oppenheimer
Target:$32.00
+123.3%from $14.33
Nov 21, 2025H.C. Wainwright
MediWound price target raised to $36 from $31 at H.C. Wainwright
Target:$36.00
+113.5%from $16.86
May 22, 2025H.C. Wainwright
MediWound price target raised to $31 from $25 at H.C. Wainwright
Target:$31.00
+52.4%from $20.34
Feb 28, 2025Craig-Hallum
Craig-Hallum starts MediWound with Buy on EscharEx potential
Target:$39.00
+134.9%from $16.60
Oct 11, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on MediWound Ltd (MDWD)
Target:$28.00
+65.5%from $16.92
May 29, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on MediWound Ltd (MDWD)
Target:$36.00
+124.9%from $16.01
Jan 4, 2023H.C. Wainwright
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $23
Target:$23.00
+73.1%from $13.29
Dec 30, 2022Cowen & Co.
Cowen & Co. Maintains Outperform on MediWound, Adjusts Price Target to $25 - 1-for-7 Reverse Stock Split
Target:$25.00
+85.3%from $13.49
Dec 22, 2022Maxim Group
Maxim Group Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $25
Target:$25.00
+127.1%from $11.01
Nov 16, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $5.5
Target:$5.50
+2205.4%from $0.24
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.